Annual Report to shareholders Sydney Morning Herald, Australia - Former Listed Company Directorships in last 3 Years Non-executive director of Australian Pharmaceutical Industries Limited, Soul Communications Limited ...ASX:KHF - ASX:SOL - EPA:MLACO
Prescription drug abuse on the rise BurlingtonFreePress.com, VT - ?We think it reflects a larger condition in society, which is that marketing by pharmaceutical companies has been so highly effective it?s influenced even ...
Allergan, Skin Filler Makers Wary of FDA Panel Report Orange County Business Journal, CA - A date for Healthaxis shareholders to vote on the deal hasn?t yet been announced. BPO intends to turn Healthaxis into its healthcare division, ...AGN
Basilea Falls as FDA Delays Ceftobiprole Decision Again BioWorld Online, GA - Nov 26, 2008 Yet, the agency's response to Basilea came as "a big surprise," Weiss said, as he had been expecting no action until the agency action date set for early ...EPA:MLACO
Closing Bell Economic Times, India - Nov 28, 2008 10:25 am: Sun Pharmaceutical Industries Ltd has said that the USFDA has granted Osmotica's Citizen Petition regarding venlafaxine extended release tablets. ...
Don't pull the plug on the Therapeutics Initiative Vancouver Sun, Canada - Nov 28, 2008 Since then, the TI has worked independently of government and the pharmaceutical industry to provide expert advice to BC's Pharmacare program, physicians, ...
AP Pharma Reports Results for the Third Quarter 2008 FOXBusiness - Nov 5, 2008 We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by ...APPA
Source: Google News
Recent News and Articles on the Keywords: 0.18 + web Related to the article below (Last Update: 8/4/2008)
Online Resources Posts Second Quarter 2008 Results WELT ONLINE, Germany - Jul 29, 2008 Online Resources Corporation (Nasdaq:ORCC), a leading provider of web-based financial services, today reported financial and operating results for the three ...ORCC
Chemtura Reports 2008 Second Quarter Results WELT ONLINE, Germany - Jul 31, 2008 Live Internet access to the 2008 second quarter conference call will be available through the Investor Relations section of the Company?s Web site. ...CEM
First Citizens Reports Earnings for Second Quarter 2008 MarketWatch - Jul 28, 2008 Nonperforming assets represent 0.42 percent of total loans and leases as of June 30, 2008 compared to 0.18 percent of loans and leases as of June 30, 2007. ...
Source: Google News
The calculation of web impact factors - P Ingwersen - Journal of Documentation, 1998 - ingentaconnect.com ... Countries in impact Web- IF Web- IF A/ inv. WIF /Web- IF web pages rank ...
1,046,961 3. France 0.886 0.42 0.46 ?0.18 ?3.47 454,822 ...
Measuring the Independence of Central Banks and Its Effect on Policy Outcomes - A Cukierman, SB Web, B Neyapti - The World Bank Economic Review, 1992 - World Bank ... Legal central bank in- depen- dence" (index) of 0.69 0.64 0.61 0.50 0.48 0.45 0.44
0.42 0.36 0.34 0.33 0.29 0.28 0.27 0.25 0.24 0.24 0.23 0.18 0.17 0.17 ...
[PDF]Data Preparation for Mining World Wide Web Browsing Patterns - R Cooley, B Mobasher, J Srivastava? - Knowledge and Information Systems, 1999 - mis.ncyu.edu.tw Page 1. Data Preparation for Mining World Wide Web Browsing Patterns ... An important
input to these design tasks is the analysis of how a Web site is being used. ...
Business use of the world-wide web - C Cockburn, TD Wilson - International Journal of Information Management, 1996 - Elsevier ... Shopping centres 1.26 1.44 +0.18 Total 99.97* 99.97* * = rounding error Web site
using the following scheme (the percentage of the sample in each class is ...
[PDF]Using Ontologies to Discover Domain-Level Web Usage Profiles - HK Dai, B Mobasher - Semantic Web Mining - km.aifb.uni-karlsruhe.de ... Property 1, 1???,??? Property 2, 0.7???,??? Property 3, 0.18???,??? Property 4, 0.18???}.
45 Page 54. Fig. 6. The Ontology of a Real Estate Web site Containing ...
[PDF]Mining Web Access Logs Using Relational Competitive Fuzzy Clustering - O Nasraoui, H Frigui, A Joshi, R Krishnapuram - Proceedings of the Eight International Fuzzy Systems …, 1999 - ai.rightnow.com Page 1. Mining Web Access Logs Using Relational Competitive Fuzzy Clustering Olfa
Nasraoui Hichem Frigui Anupam Joshi Raghu Krishnapuram Comp. Engg. & Comp. Sc. ...
[PDF]The MIT Microelectronics WebLab: a Web-Enabled Remote Laboratory for Microelectronic Device … - JA del Alamo, L Brooks, C McLean, J Hardison, G … - World Congress on Networked Learning in a Global Environment …, 2002 - www-mtl.mit.edu ... On the client side, a standard Java-enabled web browser and an Internet connection ...
by graduate students at MIT to characterize state-of-the-art 0.18 ?m CMOS ...
Real life information retrieval: a study of user queries on the Web - BJ Jansen, A Spink, J Bateman, T Saracevic - ACM SIGIR Forum, 1998 - portal.acm.org ... But in any case, this, of course, has interesting implications for recall and may
illustrate a need for high precision in Web IR algorithms ... 8 32 0.18 25 1 0.01 ...
Source: Google Scholar
US Fast Tracks Bronchitol For Cystic Fibrosis
Article Date: 24 Nov 2006 - 0:00am (PST)
Pharmaceutical company Pharmaxis (ASX:PXS, NASDAQ:PXSL) today announced that the US Food and Drug Administration (FDA) has designated Bronchitol as a fast-track product for cystic fibrosis.
The FDA fast-tracks the New Drug Application (NDA) process if a therapy can potentially address an unmet medical need for a life-threatening disease. Designation as a fast- track product is designed to expedite regulatory review of the Bronchitol NDA. The FDA and European Medicines Agency have both previously granted Bronchitol orphan drug status for treating cystic fibrosis.
Pharmaxis chief executive officer Dr Alan Robertson said: "The FDA decision is encouraging news for thousands of cystic fibrosis patients. It recognises the positive clinical data for Bronchitol in treating cystic fibrosis, which is a lethal inherited condition. "This designation will speed the process of bringing this potentially life-saving drug to cystic fibrosis sufferers.
Article continues below and (thank you)
"Phase II studies show Bronchitol significantly improves lung function and wellbeing in patients with cystic fibrosis. We look forward to working with the FDA on introducing Bronchitol to the U.S. market as rapidly as possible."
Pharmaxis is currently conducting Phase III and II clinical trials of Bronchitol in cystic fibrosis patients at sites in Europe, Canada, Argentina and Australia.
Cystic fibrosis affects approximately 75,000 people in the developed world, including 33,000 US patients and 2,500 Australians - a fifth of whom are children under five years old. There have been no treatment advances in over a decade, and no products are approved to improve lung hydration.
Designation as a fast track product enables Pharmaxis to file the new drug application on a rolling basis as data becomes available, allowing the FDA to review the application in sections ahead of receiving the complete submission. A complete submission is expected to be made in 2008.
Pharmaxis is developing Bronchitol as a treatment to improve mucus clearance in the lungs of patients with cystic fibrosis, bronchiectasis and chronic obstructive pulmonary diseases. Bronchitol is a patented, inhalable dry powder formulation of mannitol administered by a hand-held, pocket sized device.
Forward-Looking Statements
The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.
